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Abstract
Human lysosomal-associated protein multispanning membrane 5 (LAPTM5) was identified
by an ordered differential display-polymerase chain reaction (ODD-PCR) as an up-regulated
cDNA fragment during 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced differentiation
of U937 cells into monocytes/macrophages. After TPA-treatment, the levels of LAPTM5
mRNA and protein increased and reached a maximum at 18–36 h. In healthy human tissues,
LAPTM5 mRNA was expressed at high levels in hematopoietic cells and tissues, at low levels
in the lung and fetal liver, and was not detected in other non-hematopoietic tissues. LAPTM5
mRNA was detected in immature malignant cells of myeloid lineage, such as K562, HL-60,
U937, and THP-1 cells, and in unstimulated peripheral T cells, but was absent or barely
detectable in lymphoid malignant or non-hematopoietic malignant cells. The LAPTM5 level in
HL-60 cells increased more significantly during TPA-induced monocyte/macrophage differ-
entiation than during DMSO-induced granulocyte differentiation. Ectopic expression of GFP-
LAPTM5 or LAPTM5 in HeLa cells exhibited the localization of LAPTM5 to the lysosome. In
HeLa cells overexpressing LAPTM5, the Mcl-1 and Bid levels declined markedly and apopto-
sis was induced via Bak activation, Δψm loss, activation of caspase-9, -8 and -3, and PARP
degradation without accompanying necrosis. However, these LAPTM5-induced apoptotic
events except for the decline of Bid level were completely abrogated by concomitant overex-
pression of Mcl-1. The pan-caspase inhibitor (z-VAD-fmk) could suppress the LAPTM5-
induced apoptotic sub-G1 peak by ~40% but failed to block the induced Δψm loss, whereas
the broad-range inhibitor of cathepsins (Cathepsin Inhibitor I) could suppress the LAPTM5-
induced apoptotic sub-G1 peak and Δψm loss, by ~22% and ~23%, respectively, suggesting
that the LAPTM5-mediated Δψm loss was exerted at least in part in a cathepsin-dependent
manner. Together, these results demonstrate that ectopic overexpression of LAPTM5 in
HeLa cells induced apoptosis via cleavage of Mcl-1 and Bid by a LAPTM5-associated lyso-
somal pathway, and subsequent activation of the mitochondria-dependent caspase cascade.
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Introduction
Lysosomal-associated multispanning membrane protein (LAPTM5), which is preferentially
expressed in hematopoietic cells and localized to the lysosome, was initially isolated by a subtrac-
tive hybridization strategy between hematopoietic and non-hematopoietic cells [1]. LAPTM5
contains five hydrophobic transmembrane domains, with C-terminal tyrosine-based lysosomal
targeting motifs [2]. In rat cerebellar cell culture, LAPTM5 in microglia is up-regulated in res-
ponse to degeneration and apoptotic cell death of granule neurons, indicating the possible in-
volvement of LAPTM5 in microglial activation and enhancement in phagocytosis toward dead
neurons [3]. In rheumatoid arthritis, LAPTM5 is co-expressed with several known genes, which
are expressed at low levels in resting macrophages and up-regulated during macrophage activa-
tion [4]. A recent study shows that LAPTM5 is a positive regulator of proinflammatory signaling
pathways via facilitating NF-κB and MAPK signaling, and proinflammatory cytokine production
in macrophages [5]. Since lysosomes are essential in the processing of foreign antigens by profes-
sional antigen-presenting cells and digestion of ingested materials in phagocytes, LAPTM5
might be associated with the proteolytic activity of lysosomes required for phagocytosis and anti-
gen processing, and it may augment the inflammatory response in myeloid lineage immune
cells.
Yeast two-hybrid analysis reveals that LAPTM5 is an interacting partner of Smurf2, an
E3-ubiquitin ligase associated with the degradation of TGFβ signaling components that
include the TGFβ receptor and Smad proteins, in human hepatocellular carcinoma HepG2
cells [6, 7]; the expression of LAPTM5 mRNA increased 20-fold in HepG2 cells following
TGFβ treatment. Further analysis using LAPTM5 as the bait identified several LAPTM5 part-
ners, including ubiquitin, other E3 ubiquitin ligases, and proteins involved in endocytosis [7].
These results indicate that the role of LAPTM5 in lysosomal proteolysis can be extended to
non-hematopoietic cells, and suggest that LAPTM5 might be a lysosomal transporter protein
involved in the uptake of cellular proteins by the lysosome and may mediate their degradation.
Recent studies using LAPTM5-deficient mice demonstrated that LAPTM5 is essential for lyso-
somal degradation of T cell and B cell receptors and thus contributes to suppression of the cell
surface receptor-mediated activation of T and B cells [8, 9].
Besides the five membrane-spanning segments, LAPTM5 has three PY motifs (L/PPxY),
which bind the WW domains of the Nedd4 family of ubiquitin ligases, and a ubiquitin in-
teracting motif (UIM) in the C-terminus oriented toward the cytoplasmic side [9, 10]. The
interaction of the PY motif of LAPTM5 and the WW domain of NEDD4-1, a HECT-type
E3 ligase that belongs to the Nedd4 family, has been shown to be critical for the transport of
LAPTM5-positive vesicles from the Golgi to the lysosome [10, 11]. Therefore, the specific
interaction between the functional motifs of LAPTM5 and target proteins mediates the target-
ing of LAPTM5 to the lysosome and the role of LAPTM5 in lysosomal degradation of target
proteins.
In relation to the involvement of LAPTM5 in neoplastic transformation, the inactivation
of the LAPTM5 gene by chromosome rearrangement and DNA methylation is observed in
human multiple myeloma cell lines [12]. Interestingly, the accumulation of LAPTM5-positive
vesicles is associated with programmed cell death occurring during the spontaneous regression
of neuroblastomas [13]. The cell death induced in neuroblastoma cells after Adenovirus-
LAPTM5 (Ad-LAPTM5) infection is not blocked by the pan-caspase inhibitor z-VAD-fmk,
but is enhanced in the presence of both proteasomal and lysosomal inhibitors, causing the
accumulation of LAPTM5-positive vesicles. Thus, it has been suggested that the loss of
LAPTM5 can be associated with tumor progression by suppressing cell death; however,
the biochemical mechanism underlying LAPTM5-mediated cell death remains unknown.
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Furthermore, it remains obscure whether the cell death caused by the LAPTM5 accumulation
in neuroblastoma cells can be extended to cervical cancer HeLa cells.
Previously, as an attempt to isolate significantly up-regulated or down-regulated genes dur-
ing 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced terminal differentiation of U937
cells into monocytes/macrophages, we performed an ordered differential display-polymerase
chain reaction (ODD-PCR), a method of displaying the 3’-end RsaI-restriction fragments of
cDNA [14]. As a result, we could identify the human apolipoprotein C2 gene (APOC2) which
exhibits a significant enhancement in expression during TPA-induced differentiation of U937
cells [15]. In the present study, by further cloning and sequencing of the resulting cDNA
clones selected from the ODD-PCR, we found that one 113-bp cDNA clone that was signifi-
cantly up-regulated during the TPA-induced differentiation of U937 cells was the LAPTM5
gene, encoding an integral lysosomal membrane protein. The level of LAPTM5 mRNA differed
in a cell type- and tissue type-specific, as well as a malignancy-related manner. The ectopic
overexpression of LAPTM5 in human cervical epithelioid carcinoma HeLa cells resulted in
lysosomal targeting of LAPTM5, a significant reduction in cell proliferation, and induction of
apoptotic cell death, via mitochondrial damage and caspase cascade activation, without accom-
panying necrosis. The data demonstrate that LAPTM5, which was previously required for the
pro-inflammatory signaling pathway in macrophages [5] and down-regulation of T cell and B
cell receptors [8, 9], is associated with a lysosomal alliance to a mitochondrial apoptotic path-
way by reducing the anti-apoptotic Mcl-1 protein level when ectopically overexpressed in
HeLa cells.
Materials and methods
Kits, oligonucleotide primers, enzymes, reagents, bacterial strains,
media, antibodies, and cells
The SuperScripTM system for cDNA synthesis was purchased from Life Technologies (Gai-
thersburg, MD, USA). All restriction enzymes and DNA-modifying enzymes including T4
DNA ligase, RNase, and T4 polynucleotide kinase were purchased from Boehringer Mann-
heim Corp. (Indianapolis, IN, USA). An Omnibase DNA sequencing kit, Taq DNA polymer-
ase, and pGEM-T Easy Vector System I were purchased from Promega (Madison, WI, USA).
Human multiple-tissue northern blot panels I and II, human immune system multiple-tissue
northern blot panel II, and ExpressHyb hybridization solution for northern blot analysis were
obtained from Clontech Laboratories, Inc. (Palo Alto, CA, USA). 12-O-tetradecanoylphorbol
13-acetate (TPA), 3,3’-dihexyloxacarbocyanine iodide (DiOC6), 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), 4’,6-diamidino-2-phenylindole (DAPI), propidium
iodide (PI), and the cathepsin D inhibitor (Pepstatin A) were obtained from Sigma-Aldrich
(St. Louis, MO, USA). The broad range inhibitor of cathepsins (Cathepsin Inhibitor I) was
obtained from Calbiochem (San Diego, CA, USA), and the pan-caspase inhibitor z-VAD-fmk
was obtained from BD Biosciences (Chicago, IL, USA). Radioactive materials such as [γ-32P]
ATP (~3,000 Ci/mmol), [α-32P]dCTP (~3,000 Ci/mmol) and [α-35S]dATP (~1,000 Ci/mmol),
TaqStart antibody for PCR amplification, and the random primer labeling kit were obtained
from Amersham (Arlington Heights, IL, USA). The nylon membrane (GeneScreen Plus) and
[3H]TdR (2 Ci/mmol) were purchased from NEN Biotechnology System (Boston, MA, USA).
Green fluorescence protein (GFP) vector (pFP-N1) was obtained from Clontech. Escherichia
coli JM 109 used as the host strain for cDNA cloning was obtained from Promega. Bacterial
media components were obtained from Difco Laboratories Inc. (Detroit, MI, USA). Rabbit
antiserum produced against recombinant human LAPTM5 protein that was expressed using
the E. coli system was prepared as previously described [16]. The anti-caspase-3 antibody was
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purchased from Pharmingen (San Diego, CA, USA), and the anti-poly (ADP-ribose) polymer-
ase (PARP), anti-Bak, anti-Bax, anti-Bid, anti-Bcl-2, anti-Bcl-xL, anti-COX-1, anti-COX-2,
anti-NF-κB p65, and anti-Mcl-1 antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The anti-caspase-9, anti-caspase-8, and anti-IκBα antibodies were
purchased from Cell Signaling Technology (Beverly, MA, USA), and the anti-Bak (Ab-1) anti-
body was obtained from Calbiochem. The anti-APOC2 antibody was purchased from Abcam
(Cambridge, UK), and the anti-p47phox antibody was purchased from Assay Biotech (Sunny-
vale, CA, USA). The anti-GAPDH antibody was purchased from Thermo Scientific (Rockford,
IL, USA). Jurkat, Molt-3, K562, HL-60, THP-1, U937, Sup-T1, COLO 320DM, and HeLa cells
were purchased from ATCC (Manassas, VA, USA). Human peripheral T-cells were prepared
using heparinized blood obtained from healthy laboratory personnel by venipuncture as previ-
ously described [15]. This protocol was approved by the Ethics Committee of Kyungpook
National University, Daegu, Korea. Informed written consent was obtained from the partici-
pant. Human leukemias (Jurkat, Molt-3, K562, HL-60, THP-1, and U937), lymphoma (Sup-
T1), and COLO 320DM cells were maintained in RPMI 1640 (Hyclone, Gaithersburg, MD,
USA) containing 10% FBS, 20 mM HEPES (pH 7.0), 5 × 10−5 M β-mercaptoethanol, and
100 μg/ml gentamycin. HeLa cells were maintained in DMEM (Hyclone) supplemented with
10% FBS, 20 mM HEPES (pH 7.0), 1 mM sodium pyruvate, 5 × 10−5 M 2-mercaoptoethanol,
and 100 μg/ml gentamycin.
Induction of differentiation of U937 and HL-60 cells
Terminal differentiation of U937 cells into monocytes/macrophages was induced by 32 nM
TPA for 48 h as previously described [15, 17]. Differentiation of HL-60 cells into monocytes/
macrophages was induced by 32 nM TPA for 60 h, whereas differentiation of HL-60 cells into
granulocytes was induced by1.25% DMSO for 60 h [18]. To investigate growth arrest of cells
during induced differentiation, [3H]TdR-incorporation into the DNA of TPA- or DMSO-
treated cells was measured. Cells (5 × 104 cells/well) were incubated with 32 nM TPA or 1.25%
DMSO in a 96-well plate and pulsed for 4 h with 1 μCi of [3H]TdR at the times indicated. The
cells were harvested and assayed by liquid scintillation to measure the incorporation of [3H]
TdR.
Flow cytometric analyses
Flow cytometric analyses of the cell cycle in TPA-treated U937 cells were carried out as previ-
ously described [15, 19]. The extent of necrosis was determined using a FITC-Annexin V apo-
ptosis kit (Clontech, Takara Bio Inc., Shiga, Japan) as previously described [20]. The changes
in the mitochondrial membrane potential (Δψm) were measured after staining with DiOC6 as
described elsewhere [21]. The Bak activation was measured using an anti-Bak (Ab-1) anti-
body-specific for the conformationally active Bak protein as previously described [22].
ODD-PCR, DNA sequence analyses, and homology search. ODD-PCR was carried out
as previously described [14, 15]. Total RNAs extracted from control and TPA-treated (18 h
and 48 h) U937 cells were reverse transcribed with the T-primer 5'-GCGAGTCGACCG(T)13
using the SuperScript System. The synthesized double-stranded cDNA samples were digested
by RsaI, and then used for ligation with a pseudo-double-stranded adaptor (a long oligonucle-
otide, 5'-GCGTGAAGACGACAGAAAGGGCGTGGTGCGGAGGGCGGT; and a short oligonucleo-
tide, 5'-ACCGCCCTCCGC). The ligation mixture was used for PCR amplification with an
adaptor-specific primer (5'-TGTAGCGTGAAGACGACAGAA) and the T-primer. The PCR
product was used for the amplification of the simplified 3’-end cDNA subsets. Individual AdE-
primers (Adaptor-specific Extended; 5'-AGGGCGTGGTGCGGAGGGCGGTCCNN, where NN is
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GC or AG) required for the amplification were radiolabeled with [γ-32P]ATP using T4 polynu-
cleotide kinase. After the 32P-labelled AdE-primer was added to a PCR mixture containing
250 μM dNTPs, 2.5 U of Taq DNA polymerase mixed with TaqStart antibody, 0.2 μM non-
labeled TE-primer (T-Extended; 5'-GCGAGTCGACCG(T)13NN, where NN is AG, GG, GA,
GT or GC), and 1 ng of the representative 3’-end cDNA fragment sample under investigation,
the amplification reaction was performed with 23 cycles of 95˚C for 30 s, 69˚C for 30 s, and
72˚C for 90 s.
The PCR products were subjected to electrophoresis on a 6% polyacrylamide sequencing gel.
Autoradiographs were visually examined after the dried gel was exposed to X-ray film at -80˚C.
Individual DNA bands of interest on the dried gel were eluted into 20 μl of TE buffer (pH 8.0)
at 70˚C for 2 h. After the eluent was reamplified with the T-primer 5'-GCGAGTCGACCG
(T)13 and non-extended adaptor-specific primer (5'-AGGGCGTGGTGCGGAGGGCGGT) for
20 cycles, the amplified product was electrophoresed on a 2% agarose gel and purified from the
gel using the GeneClean II kit (Bio 101 Inc., Vista, CA, USA). The purified DNA fragment was
cloned using a pGEM-T Easy Vector System I and sequenced using the Omnibase DNA cycle
sequencing system. The DNA sequence was compared with reference sequences in the Gen-
Bank databases using the BLAST program.
Preparation of cell lysates and western blot analyses
Cells were suspended in the lysis buffer (137 mM NaCl, 15 mM EGTA, 1 mM sodium orthova-
nadate, 15 mM MgCl2, 25 mM MOPS, 1 mM PMSF, 5.0 μg/ml proteinase inhibitor E-64, and
0.1% Triton X-100, pH 7.2), disrupted by sonication, and extracted at 4˚C for 30 min. After
centrifugation at 16,000 × g for 20 min, the supernatant was collected. Protein quantitation
was performed using a Micro BCA kit (Pierce, Rockford, IL, USA). An equivalent amount of
protein lysate (20 μg) was electrophoresed on 4%-12% NuPAGE gradient gels (Invitrogen/
Novex, Carlsbad, CA, USA) with MOPS buffer, and then electrotransferred to Immobilon-P
membranes (Millipore Corporation, Bedford, MA, USA). Specific antibody-mediated detec-
tion of proteins on the membrane was performed using an ECL Western blotting kit (Amer-
sham, Heights, IL, USA) as previously described [20]. Densitometry was performed using
ImageQuant TL software (Amersham, Arlington Heights, IL, USA). Arbitrary densitometric
units for the protein of interest were normalized to the densitometric units of GAPDH.
Northern blot analyses
Total RNA was extracted and isolated by solubilization in guanidine thiocyanate as previously
described [19]. Equivalent amounts of total RNA (15 μg) were electrophoresed on 1% formal-
dehyde-agarose gels and transferred to nylon membranes. The nylon membrane was hybrid-
ized in ExpressHyb solution at 68˚C for 2 h with a cDNA probe radiolabeled with [α-32P]
dCTP, using the random primer labeling kit (Amersham), and washed according to the manu-
facturer’s instructions.
Transfection of HeLa cells, MTT assay, immunostaining, and
fluorescence microscopy
HeLa cells were transfected with individual plasmid DNA constructs using Effectene Transfec-
tion reagent (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. The
proliferation and cell cycle distribution of HeLa cells transfected with pCAGGS, pcDNA3.1,
pCAGGS-LAPTM5, or pcDNA3.1-Mcl-1 were analyzed by MTT assay reflecting cell viability
and flow cytometry, respectively, as previously described [19, 20]. To observe localization of
GFP and GFP-LAPTM5 under a fluorescence microscope, HeLa cells transfected with a GFP
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vector or a GFP-LAPTM5 vector were fixed with 4% paraformaldehyde for 30 min. Immunos-
taining of HeLa cells transfected with pCAGGS or pCAGGS-LAPTM5 was performed, as pre-
viously described [22]. For nuclei detection the cells were stained with 100 μM DAPI solution
for 10 min. Images were collected at × 200 magnification using an LSM 700 confocal laser
scanning microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany).
Statistical analyses
Unless otherwise indicated, each result in this paper is representative of at least three separate
experiments. Statistical analyses were performed using the Students t-test to evaluate the sig-
nificance of differences between two groups and one-way ANOVA for between three or more
than three groups. In all graphs,  indicates p< 0.05 between the untreated and treated cells.
All data are expressed as the mean ± standard deviation (SD, for each group n3). One-way
ANOVA followed by Dunnett’s multiple comparison test was also used for statistical analysis
using the SPSS Statistics version 23 (IBM, Armonk, NY, USA).
Results
Identification of differentially expressed transcripts during TPA-induced
differentiation of U937 cells
We used ODD-PCR to investigate the gene expression profiles of U937 cells during TPA-
induced differentiation into monocytes/macrophages and to identify uncharacterized genes.
Because TPA-treated U937 cells are known to stop proliferation and differentiate into mono-
cytes/macrophages, we measured the change in both the proliferative capacity and cell cycle
distribution of U937 cells during induced differentiation. As shown in Fig 1A, U937 cells
appeared to stop incorporating [3H]TdR 36 h after TPA treatment. Additionally, 36 h after
TPA treatment, there was a significant enhancement in the proportion of cells arrested in the
G1 phase, with approximately 79.6% of the cells in G1, 3.2% remaining in the S phase, and
11.5% in the G2/M phase (Fig 1B). By contrast, results from exponentially growing untreated
U937 cells showed 59.6% of the cells in G1, 24.5% in the S phase, and 14.0% in the G2/M phase.
These results indicate that treatment with 32 nM TPA caused growth arrest and induced dif-
ferentiation of U937 cells into the terminal stage. Under these conditions, ODD-PCR was per-
formed using the total RNA extracted from the exponentially growing U937 cells and U937
cells treated with 32 nM TPA for 18 h or 48 h. As a result, many bands representing PCR-
amplified 3’-end RsaI-restriction fragments of cDNAs exhibited different patterns of abun-
dance (S1 Fig). When various PCR-amplified DNA fragments with altered expression levels
were eluted from the gel, cloned, and sequenced, one of 113-bp cDNA clone, which appeared
to be significantly up-regulated during TPA-induced differentiation of U937 cells, exhibited
100% similarity with the 3’-end of human LAPTM5 gene (GenBank U51239). This nucleotide
sequence was submitted to the GenBank under the accession number AF401210.
Expression of LAPTM5 mRNA and protein during differentiation of U937
cells
We performed a northern blot analysis to quantify the expression of LAPTM5 mRNA in TPA-
treated U937 cells during induced differentiation into monocytes/macrophages. As shown in
Fig 2A, the expression of the 2.4 kb LAPTM5 mRNA, which is the only transcript detectable in
the exponentially growing U937 cells, began to increase 1 h after treatment with TPA and
reached a maximum level between 18 h and 36 h. Under these conditions, western blot analysis
showed that the LAPTM5 protein level also significantly increased in accordance with the level
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of LAPTM5mRNA (Fig 2B). The level of cyclooxygenase-2 (COX-2), which is known to con-
vert the arachidonic acid to an inflammatory mediator prostaglandin [23], was barely detected
in untreated U937 cells and its level began to increase at 6 h and reached a maximum at 36–48 h
after TPA treatment, whereas the cyclooxygenase-1 (COX-1) was detected in U937 cells at a
constant level regardless of TPA treatment. The apolipoprotein C2 (APOC2) level was elevated
and reached a maximum at 24–48 h after TPA treatment, as previously described [15]. The lev-
els of transcription factor NF-κB and its inhibitor IκBα, and p47phox that is a cytosolic compo-
nent of the NADPH oxidase complex [24], remained relatively constant. In contrast, the level of
cyclin, which accumulates in the S phase of the cell cycle and supports cellular replication [25],
Fig 1. Kinetic analysis of [3H]TdR-incorporation (A) and cell cycle distribution (B) during TPA-
induced differentiation of U937 cells. For the proliferation assay, U937 cells (5 × 104 cells/well) were
treated with 32 nM TPA in 96-well plates and pulsed for 4 h with 1 μCi of [3H]TdR at the indicated times. Each
value is expressed as the mean ± SD (n = 3 with three replicates per independent experiment). *p < 0.05
compared to the control. After equivalent cultures (2.0 × 105 cells/mL) were incubated, cells were harvested at
the indicated times and stained with PI for flow cytometry.
https://doi.org/10.1371/journal.pone.0176544.g001
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decreased and became undetectable at 24 h, coinciding with when the cells barely or no longer
incorporated [3H]TdR.
Following cell growth arrest, up-regulation of the COX-2 and APOC2 protein levels, and
down-regulation of cyclin A protein level, all of which were previously observed along with
TPA-induced differentiation of U937 cells into monocytes/macrophages [15, 17, 23, 25, 26],
were accompanied by the upregulation of LAPTM5. These results demonstrate that the
Fig 2. Kinetic analysis of the expression of LAPTM5 mRNA (A) and LAPTM5 protein (B) during
TPA-induced differentiation of U937 cells. U937 cells were treated with 32 nM TPA for the indicated time
and then total RNA and cell lysates were extracted. For northern blot analysis, total RNA (10 μg) were
electrophoresed, transferred, and probed with 32P-labeled human LAPTM5, integrin α6 subunit, and 18S
rRNA cDNA. After individual cell lysates were prepared, western blot analyses using anti-human LAPTM5,
anti-COX-1, anti-COX-2, anti-APOC2, anti-NF-κB, anti-IκBα, anti-p47 phox, anti-cyclin A, and anti-GAPDH
antibodies were performed as described in the Materials and Methods. A representative study is shown; two
additional experiments yielded similar results.
https://doi.org/10.1371/journal.pone.0176544.g002
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LAPTM5 level significantly increased during TPA-induced differentiation of U937 into mono-
cytes/macrophages.
Cell and tissue distribution of LAPTM5 mRNA
Since LAPTM5 is preferentially expressed in hematopoietic cells [1], we investigated the
expression of LAPTM5 mRNA using human multiple-tissue northern blot panels I and II and
human immune system multiple-tissue northern blot panel II, to confirm its cell and tissue
distribution. As shown in Fig 3A, in healthy human tissues, LAPTM5 mRNA was expressed at
high levels in hematopoietic cells and tissues including peripheral blood lymphocytes (PBLs),
the spleen, thymus, lymph node, and bone marrow with the most significant expression in the
PBLs, and at low levels in the lung and fetal liver. However, there was no detectable LAPTM5
mRNA in the heart, brain, placenta, liver, skeletal muscles, kidney, pancreas, prostate, testis,
ovary, small intestine, and colon (mucosal lining). These results indicate that the expression of
LAPTM5 is restricted to hematopoietic cells and tissues as well as the lung and fetal liver.
In order to determine whether the LAPTM5 gene is differentially expressed in hematopoi-
etic cells depending on myeloid- and lymphoid-lineage specificity, several malignant cells in
both the myeloid and lymphoid lineage and non-hematopoietic malignant cells were analyzed
for LAPTM5 mRNA by northern blotting. As shown in Fig 3B, LAPTM5 mRNA was detected
Fig 3. Northern blot analyses of LAPTM5-specific mRNA in various human normal tissues (A) and in
various human malignant cell lines (B). Human multiple-tissue northern membranes and human immune
system multiple-tissue northern membrane, each containing 2 μg of poly(A)+ RNA per lane, were sequentially
hybridized using 32P-labeled human LAPTM5 and β-actin cDNA. The northern blot contained 10 μg of total
RNA in each lane, which was isolated from each cell line, was hybridized with 32P-labeled human LAPTM5
and 18S rRNA cDNA.
https://doi.org/10.1371/journal.pone.0176544.g003
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in human peripheral T cells and immature malignant cells in the myeloid lineage such as
chronic myelogenous leukemia K562 cells, promyelocytic leukemia HL-60 cells, promonocytic
leukemia U937 cells, and acute monocytic leukemia THP-1 cells. LAPTM5 mRNA was absent
or hardly detected in the lymphoid malignant cells (acute T cell leukemia Jurkat cells, acute
lymphoblastic leukemia Molt-3 cells, and T cell lymphoblastic lymphoma Sup-T1 cells) and
non-hematopoietic malignant cells (colon adenocarcinoma COLO 320DM cells, and cervical
epithelioid carcinoma HeLa cells). These results indicate that LAPTM5 expression was more
dominant in hematopoietic cells in the myeloid lineage compared with those in the lymphoid
lineage, and that LAPTM5 mRNA was more abundant in resting mature hematopoietic cells
than in their immature and/or continuously proliferating counterparts.
Differential expression of LAPTM5 during lineage-specific terminal
differentiation of HL-60 cells
Previously, it was reported that HL-60 cells differentiate into monocytes/macrophages in the
presence of TPA or 1,25-dihydroxyvitamin D3, whereas the cells differentiate into granulo-
cytes upon exposure to DMSO or retinoic acid [18, 27–29]. In this context, we induced termi-
nal differentiation in HL-60 cells with TPA or DMSO, and investigated whether the expression
profile of LAPTM5 protein during TPA-induced terminal differentiation of HL-60 cells into
monocytes/macrophages differs from the expression profile during DMSO-induced terminal
differentiation of HL-60 cells into granulocytes. As shown in Fig 4A and 4B, cell growth-arrest
occurred rapidly during 32 nM TPA-induced terminal differentiation of HL-60 cells and [3H]
TdR incorporation was not detected after 48 h. The expression of LAPTM5 protein, which was
detectable at a low level in HL-60 cells, increased ~25.4-fold at 24 h; this significantly enhanced
level was sustained until 60 h after TPA-treatment. However, the rapid growth-arrest did not
occur and the LAPTM5 protein level was enhanced ~7-fold during 1.25% DMSO-induced ter-
minal differentiation of HL-60 cells into granulocytes. Additionally, the expression patterns of
COX-1, COX-2, and NF-κB proteins were similar to that of the LAPTM5 protein, in that their
levels were more significantly elevated during TPA-induced monocytic/macrophagic differen-
tiation compared to the elevation during DMSO-induced granulocytic differentiation. In con-
trast, the IκBα protein level became more prominently up-regulated during DMSO-induced
differentiation than during TPA-induced differentiation. Although the APOC2 protein was
not detected in untreated HL-60 cells, it was markedly detected between 48 h and 60 h during
TPA-induced differentiation, but not during DMSO-induced differentiation, as previously
reported [15]. The expression level of p47phox, which was clearly detected in untreated HL-60
cells, remained relatively constant irrespective of treatment with TPA or DMSO.
These results indicate that although LAPTM5 protein was expressed at a low level in HL-60
cells, its levels increased significantly during terminal differentiation into monocytes/macro-
phages and that its expression might be more important for lysosomes in macrophages than in
granulocytes.
Ectopic expression of LAPTM5 in HeLa cells
To understand the functional role of LAPTM5, we examined the effect of ectopic expression
of LAPTM5 in HeLa cells, which do not express a detectable level of LAPTM5 mRNA. To
confirm the subcellular localization of ectopically expressed LAPTM5 in HeLa cells, cells
were transfected with a GFP-LAPTM5 vector for 48 h, and the localization of GFP-LAPTM5
was visualized. As shown in Fig 5A, the GFP protein (control) was localized in both the
nucleus and the cytoplasm. However, the GFP-LAPTM5 fusion protein was localized in the
juxtanuclear region, consistent with the localization of LAPTM5 previously determined in
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Fig 4. Kinetic analysis of [3H]TdR-incorporation (A) and western blot analysis of LAPTM5 protein (B) during
TPA-induced differentiation of HL-60 cells into monocytes/macrophages or DMSO-induced differentiation of
HL-60 cells into granulocytes. For the proliferation assay, HL-60 cells (1 × 105 cells/well) were treated with 32
nM TPA or 1.25% DMSO in 96-well plates and pulsed for 4 h with 1 μCi of [3H]TdR at the times indicated.
Equivalent cultures were incubated and the cells were harvested at the indicated times for preparation of cell
lysate. Western blot analysis was performed as described in the Materials and Methods. Representative
results are presented; two additional experiments yielded similar results.
https://doi.org/10.1371/journal.pone.0176544.g004
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hematopoietic cells [1], supporting its lysosomal localization (Fig 5B). In addition, we per-
formed immunocytochemistry using the anti-LAPTM5 antibody in HeLa cells transfected
with either pCAGGS or pCAGGS-LAPTM5 to identify the subcellular localization of the
LAPTM5 protein. While HeLa cells transfected with pCAGGS showed no staining (Fig 5C),
the localization of LAPTM5 protein expressed by pCAGGS-LAPTM5 was confined to the jux-
tanuclear region, similar to the localization of the GFP-LAPTM5 fusion protein (Fig 5D). This
observation demonstrates that ectopic LAPTM5 was localized to the lysosome region of HeLa
cells.
To examine the involvement of LAPTM5 in cell proliferation and cell death, HeLa cells
transfected with pCAGGS or pCAGGS-LAPTM5 were harvested and their proliferation poten-
tials were compared by MTT assay. Although the proliferation of HeLa cells transfected with
pCAGGS was essentially the same as that of untreated HeLa cells, the proliferation of HeLa
cells transfected with pCAGGS-LAPTM5 decreased to 64% of the control (Fig 6A). Since the
average transfection efficiency of HeLa cells with pCAGGS-LAPTM5 gene was ~30% (data not
shown), these results indicate that LAPTM5 in the lysosome was associated with suppression
of cell proliferation.
Fig 5. Localization of GFP (A) and GFP-LAPTM5 (B) in HeLa cells, and immunofluorescence staining by
anti-LAPTM5 of HeLa cells transfected with pCAGGS (C) or pCAGGS-LAPTM5 (D). To observe localization
of GFP and GFP-LAPTM5, HeLa cells transfected with either a GFP vector or a GFP-LAPTM5 vector were
fixed with 4% paraformaldehyde for 30 min. For immunostaining of ectopically expressed LAPTM5 in HeLa
cells, cells transfected with pCAGGS or pCAGGS-LAPTM5 were fixed with cold methanol and stained with
rabbit polyclonal anti-human LAPTM5 antibody and DAPI as described in the Materials and Methods. Images
were visualized at ×200 using the LSM 700 confocal laser scanning microscope. Representative results are
presented; two additional experiments yielded similar results.
https://doi.org/10.1371/journal.pone.0176544.g005
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Fig 6. Effect of ectopic LAPTM5 expression on cell viability (A), cell cycle distribution (B), and apoptotic cell
death measured by FITC-Annexin V and PI staining (C) and forward scatter dot plot (D) in HeLa cells.
Untreated HeLa cells or those transfected with pCAGGS or pCAGGS-LAPTM5 were harvested 48 h after
transfection. Cell cycle distribution and apoptotic cell death were determined by flow cytometric analyses with
PI staining and FITC-Annexin V/PI double staining, respectively. The forward scatter properties of individual
unstained live, early apoptotic, and late apoptotic cells were measured to analyze changes in cell size during
the induced apoptosis. For the cell viability assay, the individual cells harvested 12 h after transfection were
added to a 96-well plate (1 × 104 cells/well) and incubated for an additional 36 h, with MTT added for the final 4
h. The cells were sequentially processed to assess the colored formazan crystal produced from MTT as an
index of cell viability. Each value is expressed as the mean ± SD (n = 3 with three replicates per independent
experiment). *p < 0.05 compared to the control. Representative results are presented; two additional
experiments yielded similar results.
https://doi.org/10.1371/journal.pone.0176544.g006
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Sequentially, to investigate whether the antiproliferative effect of ectopic LAPTM5 was
attributable to cell cycle arrest and/or apoptotic cell death, cells transfected with pCAGGS or
pCAGGS-LAPTM5 were compared with the control HeLa cells by flow cytometric analysis fol-
lowing staining either with propidium iodide (PI) or with both FITC-Annexin V and PI. As
shown in Fig 6B, although the proportion of the apoptotic sub-G1 peak in HeLa cells after
transfection with pCAGGS appeared to be 7.4%, the proportion in HeLa cells increased to
39.1% after transfection with pCAGGS-LAPTM5. At the same time, there was no remarkable
alteration in the percentage of cells in G1, S, or G2/M phase in HeLa cells following LAPTM5
transfection. As shown in Fig 6C, HeLa cells transfected with pCAGGS-LAPTM5 showed an
increase in early apoptotic cells stained with only FITC-Annexin V, and late apoptotic cells
stained with both FITC-Annexin V and PI. Under these conditions, however, the increase in
necrotic cells stained with only PI was barely detected. Although the light scattering properties
of the unstained live cells were not altered following LAPTM5 transfection, the late and early
apoptotic cells had a decrease in forward scatter, representing no cellular swelling but a reduc-
tion in cell size during LAPTM5-induced apoptosis (Fig 6D). These results indicate that
ectopic LAPTM5 expression in HeLa cells was anti-proliferative by inducing apoptosis, not
necrosis or cell cycle arrest.
To elucidate the death-signaling pathway underlying LAPTM5-mediated apoptosis in
HeLa cells, we measured the change in Δψm by flow cytometry using DiOC6 staining.
Although the level of Δψm loss in HeLa cells transfected with pCAGGS was 9.9%, the Δψm
loss was enhanced to a level of 32.7% following transfection with pCAGGS-LAPTM5 (Fig 7A).
The pro-apoptotic multidomain Bcl-2 family protein Bak has been shown to mediate permea-
bilization of the mitochondrial outer membrane, leading to mitochondrial cytochrome c
release into the cytosol and resultant activation of the caspase cascade [30, 31]. To confirm that
LAPTM5-mediated apoptotic cell death in HeLa cells is accompanied by Bak activation, we
performed flow cytometry using the conformation-specific anti-Bak (Ab-1) to analyze the N-
terminal conformational change required for Bak activation in the HeLa cells expressing
LAPTM5. As shown in Fig 7B, Bak activation was detected in HeLa cells transfected with
pCAGGS-LAPTM5, but not in HeLa cells transfected with pCAGGS. Additionally, western
blot analysis showed that HeLa cells after transfection with pCAGGS-LAPTM5 expressed
*50-fold higher level of LAPTM5 protein compared to control HeLa cells transfected with
pCAGGS, indicating ectopic overexpression of LAPTM5 (Fig 7C). In accordance with Δψm
loss and Bak activation, an ~3.2-fold reduction in anti-apoptotic Mcl-1 protein level as well as
caspase-9 activation that proceeded by proteolytic cleavage of the inactive proenzyme (47 kDa)
to the active forms (37/35 kDa) was detected (Fig 7D). In addition, caspase-8 activation
through proteolytic cleavage of the proenzyme (57 kDa) into the active forms (43/41 kDa), the
cleavage of procaspase-3 (32 kDa) into the active form (17 kDa), and PARP degradation were
detected in HeLa cells ectopically overexpressing LAPTM5. Under these conditions, the levels
of anti-apoptotic Bcl-2 family members (Bcl-2 and Bcl-xL) and pro-apoptotic Bcl-2 family
members (Bak, Bax, and Bim) remained relatively constant. The level of Bid protein (22 kDa),
which is known to be cleaved by active caspase-8 [32, 33] or lysosomal cathepsins [34, 35] to
generate truncated Bid (t-Bid, 15 kDa) causing Δψm loss and subsequent release of cyto-
chrome c, appeared to decrease by an ~4.8-fold. However, the generation of tBid was not
detected by western blot analysis in HeLa cells overexpressing LAPTM5, possibly attributable
to the short half-life of tBid. To examine whether the decline of Mcl-1 level is crucial for pro-
voking apoptotic cell death in HeLa cells overexpressing LAPTM5, we sought to determine the
protective effect of concomitant overexpression of Mcl-1 on LAPTM5 overexpression-medi-
ated apoptosis. As shown in Fig 8A, the LAPTM5-mediated apoptotic sub-G1 cells were
completely abrogated by Mcl-1 overexpression. Simultaneously, the LAPTM5-mediated
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apoptotic events including activation of caspase-9, -8 and -3, and PARP degradation were
blocked, whereas the decline in Bid level was not affected (Fig 8B). It is of interest to note that
Fig 7. Flow cytometric analyses of Δψm loss (A), Bak activation (B), and western blot analyses of LAPTM5,
Bcl-2, Bcl-xL, Mcl-1, Bak, Bax, Bid, Bim, and GAPDH (C), and activation of caspase-9, -8, and -3, PARP
cleavage, and GAPDH (D) in HeLa cells ectopically expressing LAPTM5. HeLa cells untreated and
transfected with pCAGGS or pCAGGS-LAPTM5 were harvested 48 h after transfection. Flow cytometric
analyses of Bak activation and Δψm loss, and western blot analyses were performed as described in the
Materials and Methods. Representative results are presented; two additional experiments yielded similar
results.
https://doi.org/10.1371/journal.pone.0176544.g007
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concomitant overexpression of LAPTM5 and Mcl-1 in HeLa cells produced a cleaved Mcl-1
(~35 kDa) along with the overexpressed Mcl-1 (40 kDa). However, although the level of
endogenous Mcl-1 (40 kDa) was reduced by ~2.4-fold in HeLa cells overexpressing LAPTM5
alone, the cleaved Mcl-1 was not detected presumably due to its relatively low abundance.
These results indicate that the decline of Mcl-1 level was a prerequisite for LAPTM5 overex-
pression-mediated apoptotic cell death in HeLa cells, and suggest that the decline of both Mcl-
1 and Bid levels occurred via their cleavage by the lysosomal pathway, but not by the mito-
chondrial caspase cascade pathway.
To examine further the involvement of cathepsins or caspases in the LAPTM5 overexpres-
sion- mediated apoptosis in HeLa cells, the effects of the cathepsin D inhibitor (Pepstatin A),
the pan-cathepsin inhibitor (Cathepsin inhibitor I), or the pan-caspase inhibitor (z-VAD-fmk)
on the level of apoptotic sub-G1 peak and Δψm loss were investigated in HeLa cells transfected
with pCAGGS-LAPTM5. As shown in Fig 9A and 9B, while either Cathepsin inhibitor I or
z-VAD-fmk could suppress the LAPTM5-mediated apoptotic sub-G1 peak, only Cathepsin
inhibitor I, not z-VAD-fmk, appeared to reduce the LAPTM5-mediated Δψm loss, suggesting
that the LAPTM5-mediated Δψm loss was exerted in a cathepsin-dependent manner. Under
Fig 8. Effect of Mcl-1 overexpression on the ectopic LAPTM5-induced apoptotic sub-G1 peak (A), and
changes in the level of pro-apoptotic and anti-apoptotic regulatory proteins (B) in HeLa cells. After HeLa cells
were transfected with pCAGGS/pcDNA3.1, pCAGGS-LAPTM5/pcDNA3.1, pCAGGS-LAPTM5/pcDNA3.1-
Mcl-1, or pCAGGS/pcDNA3.1-Mcl-1 for 48 h, cells were harvested and subjected to cell cycle analysis and
western blot analysis as described in the Materials and Methods. Representative results are presented; two
additional experiments yielded similar results.
https://doi.org/10.1371/journal.pone.0176544.g008
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Fig 9. Effect of the pan-caspase inhibitor (z-VAD-fmk), the pan-cathepsin inhibitor (Cathepsin inhibitor I), and
the cathepsin D inhibitor (Pepstatin A) on the ectopic LAPTM5 overexpression-induced apoptotic sub-G1 peak
(A) and Δψm loss (B) in HeLa cells. After HeLa cells were transfected with pCAGGS or pCAGGS-LAPTM5 for
12 h, 30 μM z-VAD-fmk, 2.5 μM Cathepsin inhibitor I, or 1.0 μM Pepstatin A were added to the individual cells
and incubated for an additional 36 h. The apoptotic sub-G1 peak and Δψm loss of the cells were analyzed using
flow cytometry as described in the Materials and Methods. Representative results are presented; two additional
experiments yielded similar results.
https://doi.org/10.1371/journal.pone.0176544.g009
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these conditions, neither the LAPTM5-mediated apoptotic sub-G1 peak nor Δψm loss was
markedly influenced by the cathepsin D inhibitor (Pepstatin A), excluding the involvement of
cathepsin D in the LAPTM5 overexpression-mediated apoptosis in HeLa cells.
Consequently, these results demonstrate that ectopic overexpression of LAPTM5 in HeLa
cells induced apoptotic cell death, without accompanying necrosis, via cathepsin(s)-dependent
cleavage of Mcl-1 and Bid, which rendered the cells susceptible to the onset of Bak activation
and Δψm loss, with resultant activation of caspase-9, -8, and -3, leading to PARP degradation.
Additionally, these results suggest that the caspase 8-mediated cleavage of Bid into tBid, if any,
occurred as a down-stream event of mitochondrial damage rather than an initial event that
causes mitochondrial damage.
Discussion
This is the first report to demonstrate that ectopic expression of LAPTM5 in HeLa cells causes
cathepsin-dependent cleavage of Mcl-1 and Bid, which subsequently provokes mitochondrial
pathway of apoptosis via Bak activation, Δψm loss, and activation of caspase-9, -8, and -3, lead-
ing to PARP degradation. Flow cytometric analysis of the cells after staining with FITC-An-
nexin V and PI showed no remarkable necrosis during LAPTM5 overexpression-mediated
apoptosis. The human LAPTM5 gene was identified in this study by ODD-PCR as an up-regu-
lated transcript during TPA-induced terminal differentiation of U937 cells into monocytes/
macrophages.
Previous studies show that LAPTM5 is preferentially expressed in adult hematopoietic cells
and localizes to lysosomal membranes [1]. We further investigated whether LAPTM5 mRNA
expression is restricted to hematopoietic cells. Additionally, we sought to identify any differen-
tial expression patterns between lymphoid and myeloid lineages of hematopoietic cells. To
analyze LAPTM5 mRNA expression, we performed a human multiple-tissue northern blot
and a northern blot using total RNA isolated from lymphoid lineage-malignant cells, myeloid
lineage-malignant cells, and non-hematopoietic malignant cells. In healthy human tissues,
LAPTM5 mRNA was mainly expressed at high levels in hematopoietic cells and tissues, such
as PBLs, the spleen, thymus, lymph node, and bone marrow, with a maximum expression in
PBLs. Low levels of LAPTM5 mRNA were detected in the lung and fetal liver. Additionally, the
expression of LAPTM5 mRNA was more dominant in the myeloid lineage cells (K562, HL-60,
U937, and THP-1) compared to the lymphoid lineage cells (Jurkat, Molt-3, and Sup-T1). The
level of LAPTM5 mRNA in unstimulated peripheral T cells was higher than that in immortal-
ized malignant T cell lines. These results indicate that LAPTM5 gene expression was more
abundant in mature resting hematopoietic cells than in immature and/or continuously prolif-
erating hematopoietic cells. The level of LAPTM5 mRNA in unstimulated peripheral T cells
declined after activation with anti-CD3 and anti-CD28 antibodies (data not shown). The
higher expression of LAPTM5 gene in unstimulated T cells compared with activated T cells is
compatible with the previously proposed function of LAPTM5 in T cells; namely, that—
LAPTM5 is associated with lysosomal degradation of the T cell receptor and thus down-regu-
lation of the T cell activation response [8].
The LAPTM5 protein level significantly increased during TPA-induced differentiation of
promyelocytic HL-60 cells into monocytes/macrophages; however, it increased to a lesser
extent during DMSO-induced differentiation of HL-60 cells into granulocytes. Although the
functional role of LAPTM5 in neutrophils remains unknown, it has recently been reported
that LAPTM5 augments Toll-like receptor (TLR)-inflammatory signaling pathways and the
secretion of proinflammatory cytokines in response to TLR ligands, as a critical role in macro-
phages [5]. Since the granulocytes derived from DMSO-induced differentiation of HL-60 cells
LAPTM5 overexpression causes mitochondrial damage and apoptosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0176544 May 2, 2017 18 / 23
are known to display neutrophil-like functional characteristics [28, 29, 36], and since neutro-
phils are similar to macrophages in their phagocytic and proinflammatory actions [37], cur-
rent results revealing less extensive expression of LAPTM5 in DMSO-treated HL-60 cells
compared to TPA-treated cells suggest that the LAPTM5-associated lysosomal function
required for the TLR-mediated proinflammatory response might be more prominent in mac-
rophages than in neutrophils.
While several studies have recently focused on the functional role of LAPTM5 in hemato-
poietic cells, such as macrophages and T and B lymphocytes [5, 8, 9], we sought to examine the
role of LAPTM5 in non-hematopoietic cells. We investigated the effect of ectopic expression
of LAPTM5 in HeLa cells, in which both LAPTM5 mRNA and LAPTM5 protein were not
detected by northern and western blot analyses, respectively. In our experimental model, the
ectopically expressed LAPTM5 protein in HeLa cells was translocated to the lysosome as evi-
denced by the intracellular localization of GFP-LAPTM5 and immunostaining results using an
anti-LAPTM5 antibody. Following pCAGGS-LAPTM5 transfection, the viability of HeLa cells
overexpressing LAPTM5 protein declined to ~64% of the viability of mock-transfected cells.
In addition, the levels of Δψm loss and early and late apoptotic cells stained with FITC-An-
nexin V and with FITC-Annexin V and PI, respectively, were elevated. This suggested that
apoptotic cell death, without accompanying necrosis, was induced in HeLa cells following
LAPTM5 overexpression. LAPTM5 accumulation in HeLa cells following pCAGGS-LAPTM5
transfection was accompanied by reduction of Mcl-1 and Bid levels, Bak activation, Δψm loss,
and activation of caspase-9, -3, and -8, thereby leading to PARP degradation, demonstrating
that overexpressed LAPTM5 is involved in the lysosomal contribution to activation of a mito-
chondria-dependent apoptotic pathway in HeLa cells.
Previous studies have reported that altering the expression ratio of pro-apoptotic Bcl-2 fam-
ily members (Bad, Bak, Bax, Bid, Bim, and Puma) to anti-apoptotic Bcl-2 family members
(Bcl-2, Bcl-xL, and Mcl-1) is associated with the activation of Bak and/or Bax during mito-
chondria damage-mediated apoptosis induced by chemotherapeutic agents [38, 39]. Although
the levels of Bak, Bax, Bim, Bcl-2, and Bcl-xL remained relatively constant in HeLa cells ectopi-
cally overexpressing LAPTM5, there was a significant reduction in the level of Mcl-1. At the
same time, the level of Bid (22 kDa), which can be cleaved by active caspase-8 to generate tBid
(15 kDa) causing Δψm loss [33], was significantly reduced in accordance with caspase-8 activa-
tion. Since caspase-8 was often activated downstream of caspase-3 to comprise a positive feed-
back loop involving tBid-mediated mitochondrial cytochrome c release in chemical agent-
induced apoptosis of tumor cells [40–42], current data could not exclude the possibility that
the caspase-8 activation and Bid cleavage observed in HeLa cells overexpressing LAPTM5
were due to the mitochondrial damage-mediated activation of caspase-9 and -3. Previously,
Blomgran et al. have reported that ROS-mediated lysosomal membrane permeabilization
(LMP) in neutrophils causes apoptosis via cathepsin-mediated cleavage of Mcl-1 and Bid, and
resultant mitochondrial damage and caspase activation [34]. It has also been reported that the
accumulation of LAPTM5 protein in Ad-LAPTM5-infected neuroblastoma cells induces cas-
pase-independent non-apoptotic cell death with lysosomal destabilization and LMP, which
allows lysosomal cathepsin D release into the cytosol [13]. In our experiment, the LAPTM5
overexpression-induced apoptotic sub-G1 peak in HeLa cells was reduced by ~40% in the pres-
ence of the pan-caspase inhibitor (z-VAD-fmk); however, the induced Δψm loss was not
affected, indicating that the mitochondrial damage and subsequent activation of the caspase
cascade were associated with the LAPTM5-induced apoptotic cell death. Additionally, the
pan-cathepsin inhibitor (Cathepsin inhibitor I) could suppress the LAPTM5-induced apopto-
tic sub-G1 peak and Δψm loss by ~22% and ~23%, respectively, implying the contribution of
cathepsin(s) to the Δψm loss and apoptotic cell death. However, neither the LAPTM5-induced
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apoptotic sub-G1 peak nor Δψm loss was prominently influenced by the cathepsin D inhibitor
(Pepstatin A), excluding the involvement of cathepsin D in LAPTM5 overexpression-induced
apoptosis in HeLa cells.
Recently, it has been reported that HeLa cells are sensitive to lysosomotropic drug-mediated
lysosomal disruption, which results in apoptosis induction via Bid cleavage by lysosomal
cathepsins [43]. More recently, it has also been shown that LAPTM5 overexpression in human
esophageal squamous cell carcinoma KYSE170 cells is able to promote release of cathepsins
from lysosomes and cell death [44]. These previous data are consistent with our findings in
this paper, in that LAPTM5 overexpression in HeLa cells can lead to release of lysosomal
cathepsin(s), which causes the cleavage of Mcl-1 and Bid, and resultant mitochondrial apopto-
tic cell death. However, it remains to be elucidated whether and which isoforms of lysosomal
cathepsins are responsible for the cleavage of Mcl-1 and Bid, thus reducing their levels, in
HeLa cells ectopically overexpressing LAPTM5.
In conclusion, both mRNA and protein levels of LAPTM5 were significantly up-regulated
during TPA-induced differentiation of U937 into monocytes/macrophages. While the
LAPTM5 protein level increased during TPA-induced differentiation of HL-60 cells into
monocytes/macrophages, the increase was lower during DMSO-induced differentiation of
HL-60 cells into granulocytes. In healthy human tissues, the expression of LAPTM5 mRNA
was mainly detected in hematopoietic cells and tissues as well as the lung and fetal liver; how-
ever, it was not detected in other non-hematopoietic tissues. Ectopic overexpression of
LAPTM5 in HeLa cells resulted in the localization of LAPTM5 protein to the lysosome. Addi-
tionally, cell viability declined largely due to mitochondria-dependent apoptosis resulting
from cleavage of Mcl-1 and Bid, Bak activation, Δψm loss, and activation of caspase-9, -8, and
-3, leading to PARP degradation. These results suggest that the up-regulation of LAPTM5
expression in cervical cancer may be a promising strategy for development of novel anticancer
therapies.
Supporting information
S1 Fig. ODD-PCR images for different 3’-cDNA fragments compared in three samples.
Total RNAs from untreated U937 cells and 32 nM TPA-treated (for 18 h or 48 h) U937 cells
were reverse transcribed, and sequentially the obtained 3’-end RsaI-restriction fragments of
cDNAs were amplified by PCR as described in the Materials and Methods. The PCR products
were electrophoresed on a 6% polyacrylamide sequencing gel and detection of the amplified
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